Revenue segments as reported by the company.

Companion Animal

Livestock

Contract Manufacturing & Human Health

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Interest expense

Other (income)/deductions–net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zoetis

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products, biodevices, genetic tests, and precision livestock farming technology. The firm operates through the following segments: United States & International. Its products include vaccines, parasiticides, anti-infectives, dermatology products, medicated feed additives, animal health diagnostics, and other pharmaceutical products for both companion animal and livestock customers. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zoetis reports robust 2022 results, eyes growth in key markets

Zoetis delivered strong financial performance in 2022 and projects continued growth in 2023. The company's investments in R&D, CapEx, and customer engagement strategies position it well for future competition. Challenges from inflation, competition, and supply chain issues require careful navigation, but opportunities in key growth areas offer potential for sustained success.

Zoetis reports solid Q1 results, reaffirms full-year guidance

Zoetis delivered solid Q1 results despite challenges in certain segments. The company remains optimistic about future growth opportunities, supported by upcoming product launches and strategic investments. Investor Day will provide detailed insights into Zoetis' growth strategy and innovation pipeline.

Zoetis reports robust Q2 earnings, eyes global market expansion

Zoetis delivered strong financial results in Q2 2023, with expectations of continued growth in operational revenue and adjusted net income for the full year. The company remains focused on driving revenue growth through industry tailwinds and innovation over the next few years.

Zoetis reports robust Q3 performance and anticipates accelerated growth

Zoetis' Q3 2023 performance reflects strong revenue and income growth, supported by successful product launches and a robust diagnostics portfolio.
While facing challenges from upcoming competition and margin pressures, the company remains confident in its growth prospects for 2023 and 2024.
Opportunities lie in accelerated growth driven by key products, macro trends in animal health, and ongoing investments in innovation and cost management.
Overall, Zoetis' strategic strengths position it well to navigate challenges and capitalize on opportunities for sustained growth and value creation.

Zoetis reports robust 2023 results and sets sights on international growth

Zoetis delivered strong financial performance in 2023, driven by innovative products and operational growth across portfolios. The company is well-positioned for continued growth in 2024, focusing on innovation, market leadership, and addressing challenges like currency dynamics and capacity constraints. Opportunities lie in international markets, DTC initiatives, and sustained revenue growth.

Zoetis excels in Q1 with double-digit growth and strategic focus

Zoetis' Q1 performance reflects strong revenue and income growth, driven by successful product launches and market leadership. The company's focus on innovation, quality, and strategic divestments positions it well for future growth. Challenges in livestock and competition require strategic adaptation, while opportunities in product growth and market expansion offer promising avenues for development.

Zoetis excels in Q2 2024, raises guidance and announces buyback

Zoetis' Q2 2024 performance highlights its strong market position, driven by innovative products and strategic initiatives. While challenges exist in the competitive landscape, the company's focus on customer-centric innovation and financial strength position it well for future growth. With raised guidance and shareholder value initiatives, Zoetis is poised for continued success in the animal health industry.

Zoetis reports strong Q3 earnings and eyes sustained growth

Zoetis delivered robust operational growth in Q3 2024, driven by strong performance in key segments and products, leading to a revised full year guidance and confidence in future prospects.
Despite potential challenges in navigating a dynamic landscape and supply chain efficiency, Zoetis remains well-positioned to capitalize on opportunities for growth in 2025 through innovation and market expansion.
With a focus on sustained above-industry average growth, Zoetis' strategic strengths in key franchises and market positioning reinforce their leadership in the animal health industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Illumina

Zimmer Biomet Hlds

Broader market volatility and aggressive posturing by the Federal Reserve (Fed) have had market participants searching for safe havens.

Where to invest in Q4 2022? Morningstar's top picks

Digital Realty Trust

NVIDIA

All three of these stocks are down this year. But all three have great future prospects.

3 Unstoppable Dividend Stocks That Could Soar 57% to 71%, According to Wall Street

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis has been named to Fortune's 2022 Change the World list, a global ranking of the top 50 companies making a positive social impact through business practices that are integral to their core corporate purpose. Zoetis' inclusion on the list is based on the company's African Livestock Productivity and Health Advancement (A.L.P.H.A.) initiative, which recently celebrated five years of progress establishing and developing sustainable veterinary care including

Zoetis Named to Fortune's 2022 Change the World List

While investors may be tempted to buy into Zoetis given its weakness this year, there is likely further downside. The livestock business has seen revenue decline due to generics competition and favorable tailwinds in companion animals may be fading.

A Rising Dollar May Mean Lower Zoetis Shares

PARSIPPANY, N.J. & RUTHERFORD, New South Wales, Australia--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS) today announced it has completed the acquisition of Jurox, a privately held animal health company that develops, manufactures and markets a wide range of veterinary medicines for treating livestock and companion animals. Jurox's operations are based in Australia, with additional regional offices in New Zealand, U.S., Canada and the UK. Financial terms of the transaction, which was announced in Au

Zoetis Announces the Completion of its Acquisition of Jurox, a Leading Provider of Livestock and Companion Animal Products

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #fortune500--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Nov. 3, 2022. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review third quarter 2022 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentatio

Zoetis to Host Webcast and Conference Call on Third Quarter 2022 Financial Results

Teladoc

Let's not forget one of the first rules of investing: Buy low.

2 Stocks to Buy Near Their 52-Week Lows

Takeda Pharmaceutical

TAK vs. ZTS: Which Stock Is the Better Value Option?

TAK vs. ZTS: Which Stock Should Value Investors Buy Now?

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #LifeatZoetis--For the ninth year in a row, Zoetis has been named one of Seramount's 100 Best Companies. The company was also named a Best Company for Dads.

Zoetis Named a “100 Best Company” and a “Best Company for Dads” by Seramount

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #Fortune500--Zoetis Inc. (NYSE:ZTS) will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 2:05 p.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events

Zoetis to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

TAK or ZTS: Which Is the Better Value Stock Right Now?

Elanco Animal Health Inc

Freshpet

IDEXX Laboratories

Phibro Animal Health

Despite inflationary pressures that are increasing the price of goods across the board, consumers are still pampering their pets when it comes to food.

5 Pet Care Stocks Gurus Love

Dollar General

Lowe's

These stocks have all raised their dividend payments by at least 30% within the past 12 months.

3 Dividend Stocks That Have Made Monster-Size Rate Hikes This Year

Airbnb

Datadog

dLocal Ltd

Intuit

Lam Research

Sands Capital Management recently disclosed its 13F portfolio updates for the second quarter of 2022, which ended on June 30.

Frank Sands' Top New Tech Buys

Zoetis released Q2 results last Thursday, and shares have fallen another 4% since, to 31% below their December 2021 peak. Net Income was flat year-on-year in Q2, but primarily due to currency. Operationally, revenues grew 8% and Net Income grew 9%.

Zoetis: Strong Q2 Underlying Growth But Hit By Strong U.S. Dollar

Microsoft

UnitedHealth Group

These 3 stocks are better suited to endure a recession than most.

Worried About a Recession? Buy These 3 Stocks and Hold Forever

American Tower

Cigna

Estee Lauder

Elevance Health Inc

ServiceNow

Prologis

S&P Global

Thermo Fisher Scientific

Visa

Institutional investors are big investors that generally buy shares on behalf of their clients or members.

These Are The Ten Biggest Companies With Over 90% Institutional Ownership

Zoetis' (ZTS) earnings miss estimates in second-quarter 2022. The revenues beat estimates owing to the strong uptake of the company's companion animal portfolio products.

Zoetis' (ZTS) Q2 Earnings Miss Estimates, Revenues Up

Zoetis Inc (NYSE:ZTS ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Steve Frank - Vice President of Investor Relations Kristin Peck - Chief Executive Officer Wetteny Joseph - Chief Financial Officer Conference Call Participants Michael Riskin - Bank of America Erin Wright - Morgan Stanley Jon Block - Stifel Nathan Rich - Goldman Sachs Louise Chen - Cantor Fitzgerald Elliot Wilbur - Raymond James Balaji Prasad - Barclays Ekaterina Knyazkova - JPMorgan Operator Welcome to the Second Quarter 2022 Financial Results Conference Call and Webcast for Zoetis. Hosting the call today is Steve Frank, Vice President of Investor Relations for Zoetis.

Zoetis Inc (ZTS) CEO Kristin Peck on Q2 2022 Results - Earnings Call Transcript

Zoetis (ZTS) delivered earnings and revenue surprises of -1.64% and 1.29%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zoetis (ZTS) Misses Q2 Earnings Estimates

Zoetis narrowly missed quarterly earnings estimates, though sales came in above forecasts. But Zoetis trimmed its outlook and ZTS stock fell.

Zoetis Trims Full-Year Outlook Following Mixed Second Quarter

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #Fortune500--Zoetis reports second quarter 2022 financial results.

Zoetis Announces Second Quarter 2022 Results

Alphabet

Snowflake

Lessons from 2020 and 2021 should tell you what to do.

3 Surefire Growth Stocks Destined to Double in Value

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #BoardofDirectors--Zoetis Inc. (NYSE: ZTS) today announced the appointment of Vanessa Broadhurst, Executive Vice President, Global Corporate Affairs at Johnson & Johnson, to its Board of Directors. Ms. Broadhurst has deep experience in consumer insights and direct-to-consumer advertising, and her appointment increases the size of the Board from 11 to 12 members. She will serve on the Board's Quality and Innovation Committee. “As Zoetis continues to increase its focus on pet

News for Zoetis Stock (ZTS)